1
|
Semmler G, Alonso López S, Pons M, Lens S, Dajti E, Griemsmann M, Zanetto A, Burghart L, Hametner-Schreil S, Hartl L, Manzano M, Rodriguez-Tajes S, Zanaga P, Schwarz M, Luisa Gutierrez M, Jachs M, Pocurull A, Polo B, Ecker D, Mateos B, Izquierdo S, Real Y, Ahumada A, Josef Maria Bauer D, Benjamin Mauz J, Casanova-Cabral M, Gschwantler M, Paolo Russo F, Azzaroli F, Maasoumy B, Reiberger T, Forns X, Genesca J, Bañares R, Mandorfer M. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure. J Hepatol 2024:S0168-8278(24)00198-3. [PMID: 38521170 DOI: 10.1016/j.jhep.2024.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 02/27/2024] [Accepted: 03/04/2024] [Indexed: 03/25/2024]
Abstract
BACKGROUND & AIMS Baveno VII has defined a clinically significant (i.e., prognostically meaningful) liver stiffness measurement (LSM)-decrease in cACLD by ≥20% associated with a final LSM<20 kPa, or any decrease to <10 kPa. However, these rules have not yet been validated against direct clinical endpoints. METHODS We retrospectively analysed cACLD patients (LSM≥10 kPa) with paired liver stiffness measurement (LSM) before (BL) and after (FU) HCV-cure by interferon-free therapies from 15 European centers. The cumulative incidence of hepatic decompensation was compared according to these criteria, considering hepatocellular carcinoma and non-liver-related death as competing risks. RESULTS 2335 patients followed for a median of 6 years were analysed. Median BL-LSM was 16.6 kPa with 37.1% having ≥20 kPa. After HCV-cure, FU-LSM decreased to a median of 10.9 kPa (<10 kPa: 1002 [42.9%], ≥20 kPa: 465 [19.9%]) translating into a median LSM-change of -5.3 (-8.8-[-2.4])kPa corresponding to -33.9 (-48.0-[-15.9])%. Patients achieving a clinically significant decrease (65.4%) had a significantly lower risk of hepatic decompensation (subdistribution hazard ratio [SHR]: 0.12 [95%CI: 0.04-0.35], p<0.001). However, these risk differences were primarily driven by a negligible risk in patients with FU-LSM <10 kPa (5y-cumulative incidence: 0.3%) compared to a high risk in patients with FU-LSM ≥20 kPa (16.6%). Patients with FU-LSM 10-19.9 kPa (37.4%) also had a low risk of hepatic decompensation (5y-cumulative incidence: 1.7%), and importantly, the risk of hepatic decompensation did not differ between those with/without an LSM-decrease ≥20% (p=0.550). CONCLUSIONS FU-LSM is key for risk stratification after HCV-cure and should guide clinical decision-making. LSM dynamics do not hold significant prognostic information in patients with FU-LSM 10-19.9 kPa, and thus, their consideration is not of sufficient incremental value in the specific context of HCV-cure.
Collapse
Affiliation(s)
- Georg Semmler
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | - Sonia Alonso López
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto De Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | - Monica Pons
- Liver Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Sabela Lens
- Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Liver Unit, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - Elton Dajti
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Bologna, Italy
| | - Marie Griemsmann
- Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious diseases and Endocrinology, Hannover, Germany
| | - Alberto Zanetto
- Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Padua, Italy
| | - Lukas Burghart
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria
| | | | - Lukas Hartl
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | - Marisa Manzano
- Liver Unit, Hospital Universitario 12 De Octubre, Madrid, Spain
| | - Sergio Rodriguez-Tajes
- Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Liver Unit, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - Paola Zanaga
- Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Padua, Italy
| | - Michael Schwarz
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria
| | | | - Mathias Jachs
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | - Anna Pocurull
- Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Liver Unit, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - Benjamín Polo
- Gastroenterology Unit, Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain
| | - Dominik Ecker
- Department of Internal Medicine IV, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria
| | - Beatriz Mateos
- Liver Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - Sonia Izquierdo
- Gastroenterology Unit, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - Yolanda Real
- Gastroenterology Unit, Hospital Universitario La Princesa, Madrid, Spain
| | - Adriana Ahumada
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - David Josef Maria Bauer
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria
| | - Jim Benjamin Mauz
- Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious diseases and Endocrinology, Hannover, Germany
| | | | | | - Francesco Paolo Russo
- Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Padua, Italy
| | - Francesco Azzaroli
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Bologna, Italy
| | - Benjamin Maasoumy
- Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious diseases and Endocrinology, Hannover, Germany
| | - Thomas Reiberger
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | - Xavier Forns
- Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Liver Unit, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - Joan Genesca
- Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Liver Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Rafael Bañares
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto De Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | - Mattias Mandorfer
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
2
|
Lorenzo S, Carrasco G, Parés D, Mira JJ, Natal MC, Lledó R, Vazquez F, Orrego C, Santiñà M, Izquierdo S, March JC, Zurita B, Põlluste K. Journal of Healthcare Quality Research and its first impact factor. J Healthc Qual Res 2023; 38:325-326. [PMID: 37758603 DOI: 10.1016/j.jhqr.2023.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/29/2023]
Affiliation(s)
- S Lorenzo
- Editorial Committee, Journal of Healthcare Quality Research, Spain.
| | - G Carrasco
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - D Parés
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - J J Mira
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - M C Natal
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - R Lledó
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - F Vazquez
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - C Orrego
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - M Santiñà
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - S Izquierdo
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - J C March
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - B Zurita
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| | - K Põlluste
- Editorial Committee, Journal of Healthcare Quality Research, Spain
| |
Collapse
|
3
|
Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Hepatology 2020; 72:1924-1934. [PMID: 33022803 DOI: 10.1002/hep.31588] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2020] [Revised: 09/15/2020] [Accepted: 09/22/2020] [Indexed: 12/17/2022]
Abstract
BACKGROUND AND AIMS Patients with hepatitis C virus (HCV) and advanced fibrosis remain at risk of hepatocellular carcinoma (HCC) after sustained viral response (SVR) and need lifelong surveillance. Because HCC risk is not homogenous and may decrease with fibrosis regression, we aimed to identify patients with low HCC risk based on the prediction of noninvasive markers and its changes after SVR. APPROACH AND RESULTS This is a multicenter cohort study, including patients with HCV and compensated advanced fibrosis that achieved SVR after direct antivirals. Clinical and transient elastography (TE) data were registered at baseline, 1 year, and 3 years after the end of treatment (EOT). All patients underwent liver ultrasound scan every 6 months. Patients with clinical evaluation 1 year after EOT were eligible. Univariate and multivariate Cox regression analysis were performed, and predictive models were constructed. HCC occurrence rates were evaluated by Kaplan-Meier. Nine hundred and ninety-three patients were eligible (56% male; 44% female; median age 62 years), 35 developed HCC (3.9%), and the median follow-up was 45 months (range 13-53). Baseline liver stiffness measurement (LSM) (HR 1.040; 95% CI 1.017-1.064), serum albumin (HR 0.400; 95% CI 0.174-0.923), 1-year DeltaLSM (HR 0.993; 95% CI 0.987-0.998), and 1-year FIB-4 score (HR 1.095; 95% CI 1.046-1.146) were independent factors associated with HCC. The TE-based HCC risk model predicted 0% of HCC occurrence at 3 years in patients with score 0 (baseline LSM ≤ 17.3 kPa, albumin >4.2 g/dL, and 1-year DeltaLSM > 25.5%) versus 5.2% in patients with score 1-3 (Harrell's C 0.779; log-rank 0.002). An alternative model with FIB-4 similarly predicted HCC risk. CONCLUSIONS A combination of baseline and dynamic changes in noninvasive markers may help to identify patients with a very low risk of HCC development after SVR.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antiviral Agents/therapeutic use
- Biomarkers, Tumor/blood
- Carcinoma, Hepatocellular/blood
- Carcinoma, Hepatocellular/epidemiology
- Carcinoma, Hepatocellular/pathology
- Carcinoma, Hepatocellular/virology
- Disease Progression
- Elasticity Imaging Techniques
- Female
- Follow-Up Studies
- Hepacivirus/isolation & purification
- Hepatitis C, Chronic/blood
- Hepatitis C, Chronic/drug therapy
- Hepatitis C, Chronic/pathology
- Hepatitis C, Chronic/virology
- Humans
- Liver/diagnostic imaging
- Liver/pathology
- Liver Cirrhosis/blood
- Liver Cirrhosis/drug therapy
- Liver Cirrhosis/pathology
- Liver Cirrhosis/virology
- Liver Neoplasms/blood
- Liver Neoplasms/epidemiology
- Liver Neoplasms/pathology
- Liver Neoplasms/virology
- Male
- Middle Aged
- Retrospective Studies
- Risk Assessment/methods
- Risk Factors
- Sustained Virologic Response
Collapse
Affiliation(s)
- Sonia Alonso López
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto De Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
| | | | - Francisco Gea
- Liver Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | | | | | - María José Devesa
- Gastroenterology Unit, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - Antonio Olveira
- Hepatology Unit, Hospital Universitario La Paz, Madrid, Spain
| | - Benjamin Arturo Polo
- Gastroenterology Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Laura Márquez
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | | | - Laura Rayón
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Daniel Riado
- Gastroenterology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - Sonia Izquierdo
- Gastroenterology Unit, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - Clara Usón
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Yolanda Real
- Gastroenterology Unit, Hospital Universitario La Princesa Madrid, Madrid, Spain
| | - Diego Rincón
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto De Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- Universidad Complutense de Madrid, Madrid, Spain
- Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | - Conrado M Fernández-Rodríguez
- Gastroenterology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain
- Universidad Rey Juan Carlos Madrid, Madrid, Spain
| | - Rafael Bañares
- Liver Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto De Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- Universidad Complutense de Madrid, Madrid, Spain
- Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| |
Collapse
|
4
|
Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One 2019; 14:e0225061. [PMID: 31714950 PMCID: PMC6850697 DOI: 10.1371/journal.pone.0225061] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Accepted: 10/27/2019] [Indexed: 12/27/2022] Open
Abstract
Aim We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain. Material and methods Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven “National HCV plan.” Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a non-inferiority margin of 5% and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or patients and adverse events (AEs) were also recorded. Results Overall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in each participating region in Spain. From the total population, 96.6% (95% CI, 95.8–97.3%) achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference between monoinfected and coinfected patients of −2.2% (90% CI, −4.5% - 0.2%). Only genotype 4 was associated with non-response to OBV/PTV/r ± DSV ± RBV treatment (p<0.001) in the multivariate analysis. Overall, 286 patients (11.9%) presented AEs potentially related to OBV/PTV/r ± DSV, whereas 347 (29.0%) presented AEs potentially related to ribavirin and 61 (5.1%) interrupted ribavirin. Conclusions Our results confirm that OBV/PTV/r ± DSV ± RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.
Collapse
Affiliation(s)
- José Manuel Sousa
- Hepatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Sevilla, Spain
| | - Mercedes Vergara
- Hepatology Unit, Digestive Disease Department, Parc Taulí Sabadell Hospital Universitari, Sabadell, Barcelona, Spain, CIBERehd, Instituto Carlos III, Madrid, Spain
| | - Federico Pulido
- HIV Unit, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | - Gloria Sánchez Antolín
- Hepatology Department, Hospital Universitario Río Hortega, Valladolid, Valladolid, Spain
| | - Lander Hijona
- Hepatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Álava, Spain
| | - Fernando Carnicer
- Hepatology Department, Hospital General Universitario de Alicante, Alicante, Alicante, Spain
| | - Diego Rincón
- Hepatology Department, Hospital General Universitario Gregorio Marañón, CIBERehd and (UCM), Madrid, Spain
| | - Javier Salmerón
- Hepatology Department, Complejo Hospitalario Universitario de Granada, Granada, Granada, Spain
| | | | - Antoni Jou
- HIV Clinical Unit, Internal Medicine Department and Fundació de la Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Benjamín Polo-Lorduy
- Hepatology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Ángel Rubín
- Hepatology Department, Hospital Universitario y Politécnico de La Fe, Valencia, Valencia, Spain
| | - Ana Escarda
- Hepatology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain
| | - Patricia Aguilar
- Digestive System Clinical Unit, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía/Córdoba University, Córdoba, Spain
| | - Teresa Aldámiz-Echevarría
- Infectious Diseases-HIV, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Madrid, Spain
| | - Luisa García-Buey
- Hepatology Department, Hospital Universitario de La Princesa, Madrid, Spain
| | - José A. Carrión
- Liver Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), UAB (Universitat Autonoma de Barcelona) Barcelona, Spain
| | - Manuel Hernández-Guerra
- Hepatology Department, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain
| | | | - Nuria Espinosa
- Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Infectious Diseases Research Group, Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC,Sevilla, Spain
| | - Rosa Mª Morillas
- Liver Section, Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, IGTP, Badalona, Barcelona, Spain, and CIBEREHD
| | - Raúl J. Andrade
- Unidad de Gestión Clínica de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Málaga, Spain
| | - Manuel Delgado
- Hepatology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - Adolfo Gallego
- Hepatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain
| | - Marta Magaz
- Hepatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | | | - Ángel Estébanez
- Hepatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
| | - Mikel Rico
- Infectious Diseases Unit, Hospital Universitario La Paz, Madrid, Spain
| | - Fernando Menéndez
- Hepatology Department, Hospital Universitario Basurto, Bilbao, Vizcaya, Spain
| | - Blanca Sampedro
- Hepatology Department, Hospital Galdakao, Galdakao, Vizcaya, Spain
| | - Luís Morano
- Infectious Diseases Unit, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, Spain
| | - Sonia Izquierdo
- Hepatology Department, Hospital Clínico San Carlos, Madrid, Spain
| | - José Manuel Zozaya
- Hepatology Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - Manuel Rodríguez
- Liver Unit, Division of Gastroenterology & Hepatology. Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - Senador Morán-Sánchez
- Hepatology Department, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
| | - Sara Lorente
- Hepatology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain
| | - Ignacio Martín-Granizo
- Department of Gastroenterology, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, Spain
| | | | - Marcial Delgado
- Infectious Diseases Unit, Hospital Regional Universitario de Málaga, Málaga, Spain
| | | |
Collapse
|
5
|
Lorenzo S, Carrasco G, Natal C, Parés D, Vázquez F, Mira JJ, Santinyà M, Lledó R, Izquierdo S, March JC. [Do you speak English? Yes, we do!]. J Healthc Qual Res 2018; 33:1-2. [PMID: 29358029 DOI: 10.1016/j.cali.2018.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Accepted: 12/26/2017] [Indexed: 11/30/2022]
Affiliation(s)
- S Lorenzo
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial).
| | - G Carrasco
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - C Natal
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - D Parés
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - F Vázquez
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - J J Mira
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - M Santinyà
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - R Lledó
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - S Izquierdo
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| | - J C March
- Editorial Committee, Journal of Healthcare Quality Research (formerly Revista de Calidad Asistencial)
| |
Collapse
|
6
|
Muñoz-Gómez R, Rincón D, Ahumada A, Hernández E, Devesa MJ, Izquierdo S, Ortiz M, Hernández-Albujar A, Fernández-Rodríguez C, Calvo M, González R, Lozano M, Castellano G, Fernández-Vázquez I. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J Viral Hepat 2017; 24:464-471. [PMID: 27976490 DOI: 10.1111/jvh.12664] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Accepted: 11/28/2016] [Indexed: 12/16/2022]
Abstract
Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15-29 mL/min/1.73m2 ) or 5 (eGFR<15 mL/min/1.73m2 or requiring dialysis) and HCV infection by genotypes 1 and 4 between April 2015 and October 2015 in nine Spanish centres. Sustained virological response at 12 weeks (SVR12) was assessed, and clinical and laboratory data, fibrosis stage, adverse events and pharmacological interactions were reported. Forty-six patients were included: 10 (21.7%) had CKD stage 4 and 36 (78.2%) CKD stage 5. Seventeen (36.9%) had cirrhosis. SVR12 rate in the intention-to-treat population was 95.7%. Twenty-one (45.6%) received RBV, which was discontinued in two (9.5%) patients. Anaemia (haemoglobin <10 g/dl) occurred in 12 patients (57.1%) with RBV vs 10 (40.0%) without RBV (P=.246). Renal function remained stable during antiviral therapy. Nine patients (19.5%) experienced serious adverse events unrelated to antiviral therapy. Concomitant medication was discontinued or modified in 41.3% of patients. In conclusion, the effectiveness of OBV/PTV/r±DSV±RBV in patients with CKD 4-5 was similar to that observed in those with normal renal function and was not associated with severe adverse events.
Collapse
Affiliation(s)
- R Muñoz-Gómez
- Department of Gastroenterology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - D Rincón
- Unit of Hepatology, Hospital Universitario Gregorio Marañón, CIBERehd , Madrid, Spain
| | - A Ahumada
- Unit of Hepatology, Hospital Universitario Gregorio Marañón, CIBERehd , Madrid, Spain
| | - E Hernández
- Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M J Devesa
- Department of Gastroenterology, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - S Izquierdo
- Department of Gastroenterology, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - M Ortiz
- Department of Gastroenterology, Hospital Universitario Infanta Cristina, Madrid, Spain
| | - A Hernández-Albujar
- Department of Gastroenterology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - C Fernández-Rodríguez
- Department of Gastroenterology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - M Calvo
- Department of Gastroenterology, Complejo Asistencial de Segovia, Segovia, Spain
| | - R González
- Department of Gastroenterology, Hospital Universitario del Sureste, Madrid, Spain
| | - M Lozano
- Department of Gastroenterology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - G Castellano
- Department of Gastroenterology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - I Fernández-Vázquez
- Department of Gastroenterology, Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
7
|
Dasi MA, Gonzalez-Conejero R, Izquierdo S, Padilla J, Garcia JL, Garcia-Barberá N, Argilés B, de la Morena-Barrio ME, Hernández-Sánchez JM, Hernández-Rivas JM, Vicente V, Corral J. Uniparental disomy causes deficiencies of vitamin K-dependent proteins. J Thromb Haemost 2016; 14:2410-2418. [PMID: 27681307 DOI: 10.1111/jth.13517] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Accepted: 08/08/2016] [Indexed: 08/31/2023]
Abstract
Essentials Vitamin K-dependent coagulant factor deficiency (VKCFD) is a rare autosomal recessive disorder. We describe a case of inherited VKCFD due to uniparental disomy. The homozygous mutation caused the absence of GGCX isoform 1 and overexpression of Δ2GGCX. Hepatic and non-hepatic vitamin K-dependent proteins must be assayed to monitor VKCFD treatment. SUMMARY Background Inherited deficiency of all vitamin K-dependent coagulant factors (VKCFD) is a rare autosomal recessive disorder caused by mutations in the γ-glutamyl carboxylase gene (GGCX) or the vitamin K epoxide reductase gene (VKORC1), with great heterogeneity in terms of both clinical presentation and response to treatment. Objective To characterize the molecular basis of VKCFD in a Spanish family. Methods and Results Sequencing of candidate genes, comparative genomic hybridization and massive sequencing identified a new mechanism causing VKCFD in the proband. Uniparental disomy (UPD) of chromosome 2 caused homozygosity of a mutation (c.44-1G>A) resulting in aberrant GGCX splicing. This change contributed to absent expression of the mRNA coding for the full-length protein, and to four-fold overexpression of the smaller mRNA isoform lacking exon 2 (Δ2GGCX). Δ2GGCX might be responsible for two unexpected clinical observations in the patient: (i) increased plasma osteocalcin levels following vitamin K1 supplementation; and (ii) a mild non-bleeding phenotype. Conclusions Our study identifies a new autosomal disease, VKCFD1, caused by UPD. These data suggest that the Δ2GGCX isoform may retain enzymatic activity, and strongly encourage the evaluation of both hepatic and non-hepatic vitamin K-dependent proteins to assess differing responses to vitamin K supplementation in VKCFD patients.
Collapse
Affiliation(s)
- M A Dasi
- Unidad de Hematología Pediátrica, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | - S Izquierdo
- Unidad de Hematología Pediátrica, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - J Padilla
- Centro Regional de Hemodonación, Universidad de Murcia-IMIB, Murcia, Spain
| | - J L Garcia
- Centro de Investigación del Cáncer-Universidad de Salamanca-CSIC, Salamanca, Spain
| | - N Garcia-Barberá
- Centro Regional de Hemodonación, Universidad de Murcia-IMIB, Murcia, Spain
| | - B Argilés
- Unidad de Hematología Pediátrica, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - M E de la Morena-Barrio
- Centro Regional de Hemodonación, Universidad de Murcia-IMIB, Murcia, Spain
- Grupo CB15/00055 del Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | | | - J M Hernández-Rivas
- Centro de Investigación del Cáncer-Universidad de Salamanca-CSIC, Salamanca, Spain
| | - V Vicente
- Centro Regional de Hemodonación, Universidad de Murcia-IMIB, Murcia, Spain
- Grupo CB15/00055 del Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - J Corral
- Centro Regional de Hemodonación, Universidad de Murcia-IMIB, Murcia, Spain
- Grupo CB15/00055 del Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| |
Collapse
|
8
|
Ruiz-Ortiz E, Gonzalez-Roca E, Mensa-Vilaro A, Rius J, Plaza S, Anton C, Calvo I, Modesto C, Anton J, Arnal C, Alvarez C, Alvarez-Coca J, Becerra E, Bilbao N, Camacho M, Crespo J, de Diego C, Diez-Garcia LF, Espinosa L, Garcia-Escriva D, de Gracia F, Gonzalez MI, Iglesias E, Izquierdo S, Lastra B, Llobet P, Lopez B, Lopez-Gonzalez V, Martinez R, Martin-Mateos MA, Merino R, Ortega L, Peiro ME, de Soto IP, Perez-Mendez C, Rodriguez-Valverde V, Ribes A, Ruiz A, Sanchez B, Santos JL, Sevilla B, Sotoca J, Vilas J, Villoria A, Yagüe J, Arostegui JI. Clinical and genetic features of Spanish patients with Mevalonate kinase deficiency. Pediatr Rheumatol Online J 2015. [PMCID: PMC4597073 DOI: 10.1186/1546-0096-13-s1-p36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
9
|
Salas A, Blazquez R, Bullich S, Izquierdo S, López ML, Marzana I, Vilaplana C, Ramón F. [Benchmarking and Quality Management Indicators Programme. Spanish experience]. Rev Calid Asist 2015; 30:337-341. [PMID: 26304145 DOI: 10.1016/j.cali.2015.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 06/30/2015] [Indexed: 06/04/2023]
Affiliation(s)
- A Salas
- Comisión de Acreditación de Laboratorios.
| | - R Blazquez
- Comisión de Acreditación de Laboratorios; Unidad de Calidad de Bioquímica, Departamento de Laboratorio Médico, Hospital Universitario de Móstoles, Móstoles, Madrid, España
| | - S Bullich
- Comisión de Aseguramiento Externo de la Calidad, Aseguramiento de la Calidad y Comité de Acreditación de Laboratorios, Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC), Barcelona, España
| | - S Izquierdo
- Comisión de Acreditación de Laboratorios; Servicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, España
| | - M L López
- Comisión de Acreditación de Laboratorios; Laboratorio Catlab, Departamento de Calidad, Terrassa, Barcelona, España
| | - I Marzana
- Comisión de Acreditación de Laboratorios; Laboratorio de Análisis Clínicos, Hospital San Eloy, Barakaldo, Vizcaya, España
| | - C Vilaplana
- Comisión de Acreditación de Laboratorios; Laboratori de Referència de Catalunya, El Prat, Barcelona, España
| | - F Ramón
- Comisión de Acreditación de Laboratorios
| |
Collapse
|
10
|
Devesa MJ, Cuenca F, Izquierdo S, Sánchez-Pobre P, Ladero JM, López-Alonso G, Díaz-Rubio M, Rey E. [Therapeutic update in hepatitis C]. Rev Esp Quimioter 2015; 28 Suppl 1:48-51. [PMID: 26365735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Hepatitis C virus infection is a major health burden affecting 130-170 million people worldwide. Approximately 10-30% of those with chronic hepatitis C will progress to cirrhosis over 20-30 years. The development of new direct-acting antivirals has changed the management of the disease, allowing efficacious Interferon-free therapies superior to prior treatment regimens with minimal side effects, even in some subgroups previously thought to be difficult to cure such as cirrhotic patients.
Collapse
Affiliation(s)
- María José Devesa
- María José Devesa, Servicio de Aparato Digestivo. Hospital Clínico San Carlos, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
|
12
|
Urrechaga E, Hoffmann JJML, Izquierdo S, Escanero JF. Differential diagnosis of microcytic anemia: the role of microcytic and hypochromic erythrocytes. Int J Lab Hematol 2014; 37:334-40. [DOI: 10.1111/ijlh.12290] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2014] [Accepted: 07/24/2014] [Indexed: 11/27/2022]
Affiliation(s)
- E. Urrechaga
- Hematology Laboratory; Hospital Galdakao - Usansolo; Galdakao Spain
| | - J. J. M. L. Hoffmann
- Medical and Scientific Affairs; Abbott Diagnostics; Wiesbaden-Delkenheim Germany
| | - S. Izquierdo
- Department of Genetics, Biochemical Chemistry Service; University Hospital Miguel Servet; Zaragoza Spain
| | - J. F. Escanero
- Department of Pharmacology and Physiology; Faculty of Medicine; University of Zaragoza; Zaragoza Spain
| |
Collapse
|
13
|
Moscardoó A, Ángeles Bienvenida Argilés M, Izquierdo S, Santos T, Vallés J. C0517: Hemorrhagic Diathesis in Thrombocytopenia-Absent Radius (TAR) Syndrome: Beyond Thrombocytopenia. Thromb Res 2014. [DOI: 10.1016/s0049-3848(14)50319-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Ángeles Dasí M, González-Conejero R, Izquierdo S, Padilla J, Argilés B, Corral J. C0532: Novel Mutations in the Gamma Carboxylase Gene Causing VKCFD1. Thromb Res 2014. [DOI: 10.1016/s0049-3848(14)50093-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis]. Med Clin (Barc) 2005; 125:297-300. [PMID: 16159555 DOI: 10.1157/13078423] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND AND OBJECTIVE The true prevalence of the extraintestinal manifestations (EM) associated with inflammatory bowel disease (IBD) may vary depending on the geographic area, IBD population, location and duration of the disease, medication and diagnostic accuracy. The aim of this study was determine the prevalence of the major EM of IBD and their differences between Crohn's disease (CD) and ulcerative colitis (UC). PATIENTS AND METHOD A prospective study with a total of 566 patients (295 CD with median follow up 11.6 years [range: 2-32 years] and 271 UC with median follow up 10.4 years [range: 2-36 years]. Data related to the clinical course, EM and laboratory tests were obtained at diagnosis and during follow-up. RESULTS EM related with IBD appeared al least once in 46.6% of the patients. Joints manifestations were the most common EM. The EM were equal frequent in UC (51.5%) as in CD (42.2%). Hepatobiliary manifestations (odds ratio [OR] = 1.91; 95% confidence interval [CI] 1.15-3.16; p = 0.007), venous thromboembolism (OR = 4.26; 95% CI, 1.3-15.4; p = 0.006) and arthralgias (OR = 1.59; 95% CI, 1.01-2.5; p = 0.035) were more frequent in UC than CD. Erythema nodosum (OR = 2.35; 95% CI, 1.13-5.0; p = 0.013) and peripheral arthritis (OR = 1.95; 95% CI, 1.02-3.74; p = 0.029) were more frequent in CD. The prevalences of ocular, and the rest of joint manifestations were not different according to UC or CD. CONCLUSIONS Prevalence of EM in Spanish IBD patients is among the highest ever reported. The distribution of the EM observed is different between CD and UC. It is necessary to know to allow to prompt diagnosis and prevent undesirable complications.
Collapse
Affiliation(s)
- Juan Luis Mendoza
- Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Hospital Clínico San Carlos, Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
16
|
Izquierdo S, Rey E, Gutiérrez Del Olmo A, Almansa C, Andrés Ramírez Armengol J, Díaz-Rubio M. Polyp as a complication of argon plasma coagulation in watermelon stomach. Endoscopy 2005; 37:921. [PMID: 16116545 DOI: 10.1055/s-2005-870332] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- S Izquierdo
- Digestive Disease Service, Hospital Clínico San Carlos, C/Prof Martin Lagos s/n, 28040 Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
17
|
Izquierdo S, Rey E, García Alonso M, Almansa C, Díaz-Rubio M. Has the identification of rectal hypersensitivity any implication in the clinical outcome of irritable bowel syndrome? Rev Esp Enferm Dig 2005; 97:223-8. [PMID: 15982177 DOI: 10.4321/s1130-01082005000400002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Sixty percent of patients with irritable bowel disease (IBS) are hypersensitive to rectal distension. It is uncertain to what extend the identification of this abnormality has an impact in the clinical outcome. OBJECTIVE to evaluate if rectal hypersensitivity is associated with a different clinical outcome, prognosis and use of medical resources. MATERIAL AND METHODS Patients with IBS (Rome II criteria) who underwent a rectal distension study at least one year before were eligible if they have not been included in any research protocol since then. We reviewed how many times in the last year they came to emergency room, underwent an endoscopy, and consulted a gastroenterologist or other medical physician for any reason. Also, a telephone interview was done by a gastroenterology fellow using a structured questionnaire to evaluate the frequency and severity of their symptoms in the last year and last month. RESULTS A total of 52 patients were eligible and 38 were included. Fourteen were not included because inability to made a phone contact or did not consent to phone interview. Twenty six patients were hypersensitive and 12 normosensitive. Both groups had similar symptoms (frequency and severity) but hypersensitive patients visited less to the gastroenterologist (1.2 +/- 0.2 vs. 2.9 +/- 0.6 times yearly, p < 0.01). CONCLUSION Identification of rectal hypersensitivity to distension is associated to less consultation to gastroenterologist, although severity and frequency of symptoms are not modified. Finding of an objective explanation of the symptoms seems to help patients to understand their disease, leading to a decrease in resources use.
Collapse
Affiliation(s)
- S Izquierdo
- Service of Digestive Diseases, Hospital Clínico San Carlos, Madrid, Spain
| | | | | | | | | |
Collapse
|
18
|
|
19
|
|